(INNF)
BOCOCIZUMAB(INNS)
BOCOCIZUMAB(INND)
BOKOCIZUMAB(INNC)
IMMUNOGLOBULIN G2-KAPPA, ANTI-[HOMO SAPIENS PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, NEURAL APOPTOSIS-REGULATED CONVERTASE 1, NARC1, NARC-1, PROPROTEIN CONVERTASE 9, PC9)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA2 HEAVY CHAIN (1-444) [HUMANIZED VH (HOMO SAPIENS IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -HOMO SAPIENS IGHG2*01 (CH1 (119-216), HINGE (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-13*02 (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01 (108'- 214')]; DIMER (220-220":221-221":224-224":227-227")- TETRAKISDISULFIDE, RECOMMENDED INN: LIST 72(WHO)
BOCOCIZUMABUM(INN)